CRP Adverse Event Reporting & Safety Monitoring 2

Question 1

Causality assessment in adverse event reporting refers to:

Accepted Answer

Evaluating the likelihood that the investigational product caused the adverse event

Answer

Determining the participant's personal responsibility for the event

Answer

Calculating the financial cost of managing the adverse event

Answer

Identifying which study staff member initially observed the event

Question 2

The Common Terminology Criteria for Adverse Events (CTCAE) is a standardized system used to:

Accepted Answer

Grade adverse event severity on a numerical scale from 1 to 5

Answer

Define which adverse events require immediate IRB notification

Answer

Determine financial compensation owed to research participants

Answer

Assign legal liability for adverse events in clinical trials

Question 3

Which of the following is NOT among the standard regulatory criteria for classifying an adverse event as 'serious'?

Accepted Answer

Resulted in an isolated clinically significant laboratory abnormality

Answer

Required inpatient hospitalization or prolongation of existing hospitalization

Answer

Resulted in persistent or significant disability or incapacity

Answer

Was life-threatening

Question 4

In clinical trial practice, who is primarily responsible for assessing the causal relationship between the investigational product and an adverse event?

Accepted Answer

The principal investigator or a qualified designee

Answer

The IRB chairperson

Answer

The sponsor's biostatistician

Answer

The FDA medical officer assigned to the IND

Question 5

What is the primary purpose of an IND Safety Report submitted by a sponsor to the FDA?

Accepted Answer

To promptly inform FDA and all investigators of unexpected serious adverse drug reactions

Answer

To notify the IRB of annual protocol amendments

Answer

To document routine adverse events in the case report form

Answer

To request FDA approval for a protocol-specified dose escalation

Question 6

Under FDA regulations, when a sponsor receives or becomes aware of a fatal or life-threatening unexpected serious adverse drug reaction, they must notify FDA within 7 days and:

Accepted Answer

Notify all investigators as soon as possible, also within 7 calendar days

Answer

Immediately suspend the IND pending FDA review

Answer

Unblind all participants at all sites

Answer

Convene an emergency DSMB meeting before reporting

Question 7

When an investigator receives an IND Safety Report from the sponsor, the investigator is required to:

Accepted Answer

Submit it to the IRB as required by IRB policy and assess impact on participants

Answer

Re-consent all current participants immediately

Answer

Submit a copy to the FDA within 5 business days

Answer

Discontinue all participants from the study pending review